Rovi jumps after raising 2026 outlook on strong third-quarter beat

By Reuters News

** Shares in Rovi ROVI.MC jump about 8% after the Spanish pharmaceutical company reported better-than-expected third quarter results and increased its guidance for 2026

** Banco Sabadell broker said third-quarter EBITDA reached €105.4 million ($118.69 million), above €78 million consensus estimates and €83 million estimated by the broker

** Operating revenue for the full year is now expected to grow by a mid-to-high single-digit percentage, higher than the low-to-mid single-digit growth previously forecast, Renta4 broker said

** Renta4 highlighted Rovi's contract manufacturing business (CDMO) strong performance, where third-quarter revenue rose 51% year-on-year, benefiting from higher customer activity and contributions from its agreement with Bristol Myers Squibb

** Shares are on track for their best day since July 2023

($1 = 0.8880 euros)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.